Vitilimus 0.1% Cream | 30g Tube

✔️ Uses of Vitilimus 0.1% Cream

Atopic dermatitis

✔️ Directions for Use: Vitilimus 0.1% Cream

• For topical use only
• Clean and dry the affected area before applying
• Apply a thin layer and gently massage until fully absorbed
• Wash hands after application unless hands are in the treated area
• Avoid contact with eyes, mouth, or mucous membranes
• Do not cover with occlusive dressings unless instructed

✔️ Mechanism of Action: Vitilimus 0.1% Cream

Tacrolimus suppresses immune responses by binding to FKBP-12, forming a complex that inhibits the calcineurin enzyme. This blocks T-lymphocyte activation and reduces cytokine production, ultimately leading to decreased skin inflammation.

✔️ Dosage & Administration of Vitilimus 0.1% Cream

Adults:
Apply Tacrolimus 0.03% or 0.1% ointment twice daily. Rub in thoroughly. Use for short-term and intermittent therapy. If there's no improvement within 6 weeks, reevaluate the diagnosis.

Pediatrics:

Under 2 years: Not recommended

Ages 2–15 years: Use 0.03% ointment, apply twice daily

Over 15 years: Use 0.03% or 0.1% ointment every 12 hours

✔️ Common Side Effects

• Application site burning (43–58%)
• Itching or pruritus (41–46%)
• Flu-like symptoms (23–31%)
• Skin redness or erythema (12–28%)
• Headache (5–20%)

✔️ Drug Interactions

Use caution when combining Tacrolimus with other agents, especially:

• Nephrotoxic drugs (e.g., aminoglycosides, cisplatin, NSAIDs)
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, HIV protease inhibitors)
• Drugs causing hyperkalemia (e.g., potassium-sparing diuretics)
• Drugs that reduce Tacrolimus levels (e.g., phenytoin, rifampin, carbamazepine)
• Concomitant use with Sirolimus can reduce blood levels of both medications.

✔️ Pregnancy & Lactation

Pregnancy Category C: Not enough data on safety in pregnant women

Breastfeeding: Unclear whether topical Tacrolimus passes into breast milk. Use only if the benefits outweigh the potential risks

✔️ Precautions

• Do not use on large body surfaces (>50% BSA) or broken skin
• Treat any active skin infections before starting therapy
• Avoid in patients with Netherton's syndrome or unexplained lymphadenopathy
• Use with caution on the face or neck
• Monitor patients at risk for systemic absorption
• Avoid prolonged, continuous use unless directed